Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

LBM415 is a peptide deformylase inhibitor active against gram-positive bacterial species and some gram-negative species. In multiselection studies, LBM415 had low MICs against all Streptococcus pneumoniae strains tested, regardless of their genotype, and selected resistant clones after 14 to 50 days. MIC increases correlated with changes mostly in the 70GXGXAAXQ77 motif in peptide deformylase. The postantibiotic effect of LBM415 ranged from 0.3 to 1.4 h.

Knowledge Graph

Similar Paper

Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents
Antimicrobial Agents and Chemotherapy 2007.0
In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models
Antimicrobial Agents and Chemotherapy 2009.0
Reduced Susceptibility of Haemophilus influenzae to the Peptide Deformylase Inhibitor LBM415 Can Result from Target Protein Overexpression Due to Amplified Chromosomal def Gene Copy Number
Antimicrobial Agents and Chemotherapy 2007.0
Identification of novel potent bicyclic peptide deformylase inhibitors
Bioorganic & Medicinal Chemistry Letters 2004.0
Hydroxamic Acid Derivatives as Potent Peptide Deformylase Inhibitors and Antibacterial Agents
Journal of Medicinal Chemistry 2000.0
Peptide deformylase inhibitors with activity against respiratory tract pathogens
Bioorganic & Medicinal Chemistry Letters 2004.0
Capability of 11 Antipneumococcal Antibiotics To Select for Resistance by Multistep and Single-Step Methodologies
Antimicrobial Agents and Chemotherapy 2007.0
Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria
European Journal of Medicinal Chemistry 2014.0
Antistaphylococcal Activity of CG400549, a New Experimental FabI Inhibitor, Compared with That of Other Agents
Antimicrobial Agents and Chemotherapy 2007.0
In Vitro Activities of the Lipopeptides Palmitoyl (Pal)-Lys-Lys-NH <sub>2</sub> and Pal-Lys-Lys Alone and in Combination with Antimicrobial Agents against Multiresistant Gram-Positive Cocci
Antimicrobial Agents and Chemotherapy 2007.0